



JOINT STATEMENT ON MEDICATIONS TO TREAT COVID-19

**Alaska Board of Pharmacy
Alaska State Medical Board
Alaska Board of Nursing**

April 8, 2020

As professional organizations, licensing boards, and state and federal organizations respond to emerging issues surrounding the novel coronavirus, many entities are issuing joint statements in an effort to provide more comprehensive guidance to providers, regulatory agencies, and the public. The Alaska Board of Pharmacy, State Medical Board, and Board of Nursing first convened on March 16, 2020 in an effort to address a myriad of concerns affecting scope of practice, limitation of services, staffing shortages, and emerging topics, including treatment of Covid-19 using hydroxychloroquine, chloroquine, and azithromycin. The boards collectively feel that stockpiling or hoarding of these medications is not warranted and that we all must do our part as healthcare team members to ensure such practices don't take place. Such instances can rapidly have a negative impact on immediate and future supply of these medications, and can make it very difficult on patients who are currently on the treatment for other approved medical conditions.

Richard Holt Digitally signed by Richard Holt
Date: 2020.04.06 15:38:23
-08'00'

Richard Holt, RPH – Chair, Board of Pharmacy

Richard Wein, M.D.

Richard Wein, MD – Chair, Medical Board

Danette Schloeder Digitally signed by Danette
Schloeder
Date: 2020.04.06 11:13:49 -08'00'

Danette Schloeder, RN – Chair, Board of Nursing

D. Nielsen

Endorsed by the Board of Dental Examiners
David Nielson, DDS – Chair